

IAP9 Rec'd PCT/PTO 31 JAN 2006

INFORMATION DISCLOSURE STATEMENT

Applicant : Jin, et al.
App. No : Unknown
Filed : Herewith
For : PHARMACEUTICAL COMPOSITION
FOR ORAL ADMINISTRATION
Examiner : Unknown
Art Unit : Unknown

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 18 references to be considered by the Examiner. Seventeen references are enclosed.

This Information Disclosure Statement is being filed upon the filing date of the application and no fee is required.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Jan. 31, 2006

By: Chele Chereskin

Chele Chereskin, Ph.D.
Registration No. 41,466
Agent of Record
Customer No. 20,995
(949) 760-0404

2321632
012406

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.R./

IAP9 Rec'd PCT/PTO 31 JAN 2016

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Multiple sheets used when necessary)

SHEET 1 OF 2

Application No.	
Filing Date	Herewith
First Named Inventor	Jin, et al.
Art Unit	Unknown
Examiner	Unknown
Attorney Docket No.	TOYA145.001APC

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		2004/253314	12/16/04	Peterit, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country-Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
		WO 96/15786	05/30/96	Glaxo Wellcome, Inc.		
		WO 98/00159	01/08/98	Oxigene, Inc.		
		WO 99/20285	04/29/99	Sanwa Kagaku Kenkyusho Co., Ltd.		Abstract
		WO 01/66083	09/13/01	Taisho Pharmaceutical Co., Ltd.		Abstract
		WO 01/89476	11/29/01	NPD LLC		
		WO 02/074100	09/26/02	Taisho Pharmaceutical Co., Ltd.		Abstract
		EP 0 379 147	07/25/90	Sterling Drug Inc.		
		EP 1 031 345	08/30/00	Sanwa Kagaku Kenkyusho Co., Ltd.		
		JP 10-236980	09/08/98	Hisamitsu Pharmaceutical Co., Inc.		Abstract
		JP 11-092402	04/06/99	Eisai Co., Ltd.		Abstract
		JP 11-322606	11/24/99	Kobayashi Seiyaku Kogyo KK		Abstract
		JP 2001-114696	04/24/01	Ohta Pharmaceutical Co., Ltd.		Abstract

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
		Leak, et al. "Pharmaceutical Development of Ondansetron Injection," <i>European Journal of Cancer & Clinical Oncology</i> , Vol. 25, Suppl. 1, pp. 567-569, 1989.	
		Liácer, et al. "Adsorption-Desorption of Ondansetron on Latex Particles," <i>Drug Development and Industrial Pharmacy</i> , Vol. 26, No. 3, pp. 237-242, 2000.	
		Quercia, et al. "Stability of Granisetron Hydrochloride in an Extemporaneously Prepared Oral Liquid," <i>American Journal of Health-System Pharmacy</i> , Vol. 54, pp. 1404-1406, June 15, 1997.	

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.R./
T¹ - Place a check mark in this area when an English language translation is attached.

AP9 Rec'd PCT/PTO 31 JAN 2006*

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Multiple sheets used when necessary)

SHEET 2 OF 2

Application No.	10/566829
Filing Date	Herewith
First Named Inventor	Jin, et al.
Art Unit	Unknown
Examiner	Unknown
Attorney Docket No.	TOYA145.001/APC

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
		Ruiz, et al. "Physical Characteristics of Polymer Complexes in Suspension Obtained from Cellulosic Latexes with Ondansetron," <i>Journal of Materials Science: Materials in Medicine</i> , Vol. 15, pp. 659-664, 2004.	
		International Search Report	

2321326
012406

Examiner Signature /Craig Ricci/ Date Considered 06/03/2008

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check-mark in this area when an English language translation statement is present. ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.R./